|
Company:
|
GERON CORP (GERN)
|
|
Form Type:
|
SC 13G/A
|
|
Filing Date:
|
2/17/1998
|
|
CIK:
|
0000886744
|
|
Address:
|
149 COMMONWEALTH DRIVE
SUITE 2070
|
|
City, State, Zip:
|
MENLO PARK, California 94025
|
|
Telephone:
|
(650) 473-7700
|
|
Fiscal Year:
|
12/31
|
|
|
|
|
|
Last Trade
|
Last Trade:
$1.48
|
Change:
0.00 (0.00%)
|
Trade Time:
Nov 11
|
Market Cap:
$295.67M
|
|
|
|
|
|
|
Description of Business
|
|
We are a late-stage clinical biopharmaceutical company that is focused on the
development and commercialization of innovative therapeutics for hematologic
myeloid malignancies. We have global rights to imetelstat, a first-in-class
telomerase inhibitor, that was discovered and developed at Geron. We believe
clinical data from two Phase 2 clinical trials of imetelstat (IMerge and IMbark,
discussed below) conducted by Janssen Biotech, Inc., or Janssen, support further
development of imetelstat in hematologic myeloid malignancies. We are working
with Janssen to transition the imetelstat program to us. See further discussion
below regarding our past and current relationship with Janssen.
|
|
|
|